Pulmonary complications associated with sugammadex or neostigmine in patients recovering from advanced diagnostic or interventional bronchoscopy: a retrospective two-centre analysis
Main findingResult — go to the resultOdds ratio 1.44 95% CI 1.02–2.05Authors' conclusion
Sugammadex was associated with a higher risk of PPCs than neostigmine. However, the absolute difference observed (0.8%) might not be clinically meaningful.
Study context
- Population
- Patients undergoing diagnostic or interventional bronchoscopy under GA with neuromuscular blockers, July 2016–June 2022bronchoscopies in 6123 patients
- Participants
- 8,557 patients
- Exposure
- Sugammadex vs neostigmine for NMB reversal
- Sugammadexn = 3,830
- Neostigminen = 4,727reference
- Outcome
- Composite of postoperative pulmonary complications (PPCs)
Methodological detailstwo-centre, inverse probability of treatment weighting
- Two-centre
- Inverse probability of treatment weighting
Main finding
As reported in the abstract
Odds ratio
1.44
95% CI 1.02–2.05
P = 0.038
Events by group
Sugammadex vs Neostigmine
OR 1.44 (95% CI 1.02–2.05); P = 0.038
Observational data: associations, not effects.
Secondary outcomes
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Hypoxaemia | 0.98 (0.81–1.20) | P = 0.878 | |
| 0.512Odds ratio (log scale) |
Original publication
Pulmonary complications associated with sugammadex or neostigmine in patients recovering from advanced diagnostic or interventional bronchoscopy: a retrospective two-centre analysis. Br J Anaesth. Published 14 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →